A putative therapeutic target in triple negative breast cancer: O15392

Ablatotech Signals reports today on a putative therapeutic target — O15392 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in triple negative breast cancer.

Background

The putative target O15392 has been identified as a candidate of interest in the study of triple-negative breast cancer (TNBC), a subtype known for its aggressive behavior and lack of targeted therapies. TNBC poses significant treatment challenges due to its heterogeneity and the absence of hormone receptors. Investigating O15392 may uncover novel biological pathways and therapeutic opportunities, thus warranting further exploration in the context of TNBC.

Data-mining rationale

The identification of O15392 as a putative target was achieved through a systematic cross-referencing of UniProt's reviewed human entries related to TNBC with 253 microarray datasets from the NCBI Gene Expression Omnibus (GEO). O15392 was found to be present in several expression-profiling studies, yet it currently lacks any registered Phase 1 or higher clinical programs. This absence highlights a potential oversight in the clinical development landscape for this candidate.

Why prior analyses may have missed this

A significant number of the GEO datasets analyzed in this study were generated prior to the implementation of modern empirical-Bayes statistical methods, such as limma, which are critical for accurate data interpretation. The lack of rigorous multiple-testing correction in earlier analyses may have contributed to the underappreciation of candidates like O15392. A re-analysis using contemporary statistical techniques could reveal new insights into its expression and relevance in TNBC.

Reasoning for further validation

To further investigate the potential role of O15392 in TNBC, the following experimental approaches are recommended: 1. Re-analyze the matched GEO datasets utilizing the limma package with Benjamini-Hochberg false discovery rate (FDR) set to < 0.05 to accurately identify differentially expressed genes. 2. Validate the top differentially expressed genes associated with O15392 through quantitative PCR (qPCR) in an independent cohort to confirm expression patterns. 3. Assess the tissue specificity of O15392 using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to evaluate its relevance in breast tissue. 4. Conduct pathway analysis using tools like STRING and OmniPath to explore the biological context and potential interactions involving O15392. 5. If validation is successful, evaluate the druggability of O15392 through databases such as DGIdb and ChEMBL to assess its potential as a therapeutic target.

References